IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory iNHL. Adults with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) after ≥2 lines of thera...

Full description

Bibliographic Details

Published in:	Clinical lymphoma, myeloma and leukemia Vol. 20; p. S278
Main Authors:	Jacobson, Caron A., Chavez, Julio C., Sehgal, Alison R., William, Basem M., Munoz, Javier, Salles, Gilles, Casulo, Carla, Munshi, Pashna N., Maloney, David G., Vos, Sven de, Reshef, Ran, Leslie, Lori A., Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Fung, Henry C., Plaks, Vicki, Yang, Yin, Lee, Jennifer, Avanzi, Mauro P., Neelapu, Sattva S.
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01.09.2020
Subjects:	CAR T cell therapy chimeric antigen receptor IBCL indolent B-cell lymphoma IBCL chimeric antigen receptor CAR T cell therapy indolent B-cell lymphoma
ISSN:	2152-2650, 2152-2669
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!